Literature DB >> 17475810

UR-1505, a new salicylate, blocks T cell activation through nuclear factor of activated T cells.

Juan Román1, Alberto Fernández de Arriba, Sonia Barrón, Pedro Michelena, Marta Giral, Manuel Merlos, Elvira Bailón, Mònica Comalada, Julio Gálvez, Antonio Zarzuelo, Isabel Ramis.   

Abstract

2-Hydroxy-4(-2,2,3,3,3-pentafluoropropoxy)-benzoic acid (UR-1505), a new molecule chemically related to salicylic acid, has immunomodulator properties and is currently under clinical development for treatment of atopic dermatitis. The present work describes the immunomodulatory profile of UR-1505. UR-1505 targets T cells, inhibiting their proliferation and cytokine production by blocking nuclear factor of activated T cells (NF-AT) DNA-binding activity. The effects of UR-1505 (100-300 microM) on T cell proliferation seems to be dependent on the stimulus, because UR-1505 inhibited CD3/CD28-induced T-cell proliferation, increased p27(KIP) levels, and induced G1/S cell arrest but, interestingly, did not inhibit the Janus tyrosine kinase/signal transducer and activator of transcription-induced T-cell proliferation. These data suggest that UR-1505 acts by means of a specific mechanism inhibiting T cell activation depending on T cell receptor signaling pathway. Furthermore, the antiproliferative effects of UR-1505 are not a consequence of decreased cell viability. In addition to the inhibition of T-cell proliferation, UR-1505 decreased, in a dose-dependent manner, the production of interleukin (IL)-5 and interferon (IFN)-gamma in activated T cells, and this effect was produced at the transcriptional level. Because T-cell proliferation and cytokine production were regulated through NF-AT, we examined the effect of UR-1505 on this transcription factor. According to its effect on IL-5 and IFN-gamma mRNA expression, UR-1505 specifically inhibited NF-AT DNA binding without effect on nuclear factor-kappaB and activator protein-1 activities. The effect of UR-1505 on NF-AT is not attributable to a blockade of nuclear import. In conclusion, UR-1505 is a new immunomodulator agent that specifically inhibits NF-AT activation. Because NF-AT regulates the transcription of most genes involved in lymphocyte activation, its selective inactivation results in both decreased T-cell proliferation and cytokine production.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17475810     DOI: 10.1124/mol.107.035212

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

Review 1.  NFAT as cancer target: mission possible?

Authors:  Jiang-Jiang Qin; Subhasree Nag; Wei Wang; Jianwei Zhou; Wei-Dong Zhang; Hui Wang; Ruiwen Zhang
Journal:  Biochim Biophys Acta       Date:  2014-07-26

Review 2.  Inflammation as a Therapeutic Target for Diabetic Neuropathies.

Authors:  Rodica Pop-Busui; Lynn Ang; Crystal Holmes; Katherine Gallagher; Eva L Feldman
Journal:  Curr Diab Rep       Date:  2016-03       Impact factor: 4.810

3.  Mutation of cysteine 46 in IKK-beta increases inflammatory responses.

Authors:  Ting Li; Vincent Kam Wai Wong; Zhi Hong Jiang; Shui Ping Jiang; Yan Liu; Ting Yu Wang; Xiao Jun Yao; Xiao Hui Su; Feng Gen Yan; Juan Liu; Elaine Lai-Han Leung; Xiao Qin Yi; Yuen Fan Wong; Hua Zhou; Liang Liu
Journal:  Oncotarget       Date:  2015-10-13

4.  Topical Therapy in Atopic Dermatitis in Children.

Authors:  Dharshini Sathishkumar; Celia Moss
Journal:  Indian J Dermatol       Date:  2016 Nov-Dec       Impact factor: 1.494

Review 5.  Revisiting the Concept of Targeting NFAT to Control T Cell Immunity and Autoimmune Diseases.

Authors:  Jae-Ung Lee; Li-Kyung Kim; Je-Min Choi
Journal:  Front Immunol       Date:  2018-11-27       Impact factor: 7.561

6.  Novel inhibitors of the calcineurin/NFATc hub - alternatives to CsA and FK506?

Authors:  Matthias Sieber; Ria Baumgrass
Journal:  Cell Commun Signal       Date:  2009-10-27       Impact factor: 5.712

Review 7.  NSAIDs, Mitochondria and Calcium Signaling: Special Focus on Aspirin/Salicylates.

Authors:  Yoshihiro Suzuki; Toshio Inoue; Chisei Ra
Journal:  Pharmaceuticals (Basel)       Date:  2010-05-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.